Following the cloning of the H3R in 1999 (58), numerous ligands were developed to manipulate the function of the receptor, and the H3R was subsequently proposed as a potential therapeutic target for the treatment of obesity (81, 116, 181, 182). This evidence concerns the gene HRH3 and obesity disorder.